SCHEMBL3045194

SCHEMBL3045194

Fc1c(Br)ccc2[nH]cnc12

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.44
KMT2A Q03164 3/20 0.44
ALDH1A1 P00352 2/20 0.44
MAPT P10636 2/20 0.44
PRNP P04156 1/20 0.44
HPGD P15428 1/20 0.44
HTT P42858 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
MMP12 P39900 1/20 0.41
LMNA P02545 2/20 0.40
POLB P06746 1/20 0.39
CSNK2A2 P19784 1/20 0.36
RAB9A P51151 1/20 0.36
CSNK2B P67870 1/20 0.36
CSNK2A1 P68400 1/20 0.36
DYRK1A Q13627 1/20 0.36
CSNK2A3 Q8NEV1 1/20 0.36
PARP1 P09874 2/20 0.36
DPP4 P27487 2/20 0.36
PKM P14618 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1193116 0.79 LMNA (0.42) MEN1KMT2AALDH1A1MAPTPRNP
SCHEMBL29961305 0.79 LMNA (0.42) MEN1KMT2AALDH1A1MAPTPRNP
SCHEMBL3045187 0.76 MEN1 (0.44) MEN1KMT2AALDH1A1MAPTPRNP
SCHEMBL21551313 0.76 MEN1 (0.41) MEN1KMT2AALDH1A1MAPTPRNP
SCHEMBL3050486 0.76 MEN1 (0.44) MEN1KMT2AALDH1A1MAPTPRNP
SCHEMBL24463297 0.76 LMNA (0.40) MEN1KMT2AALDH1A1MAPTPRNP
SCHEMBL19329692 0.76 PARP1 (0.40) MEN1KMT2AALDH1A1MAPTPRNP
SCHEMBL20975555 0.76 MAPT (0.43) MEN1KMT2AALDH1A1MAPTPRNP
SCHEMBL18964905 0.76 LMNA (0.40) MEN1KMT2AALDH1A1MAPTPRNP
SCHEMBL16972836 0.76 MEN1 (0.53) MEN1KMT2AALDH1A1MAPTPRNP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250122181-A1 BENZIMIDAZOLES AS MODULATORS OF IL-17 JANSSEN PHARMACEUTICA NV (BE) 2025-04-17 US disclosed
EP-4408837-A1 BENZIMIDAZOLE AND AZABENZIMIDAZOLE IL-17 INHIBITOR COMPOUNDS JANSSEN Pharmaceutica NV (BE) 2024-08-07 EP disclosed
CN-118139859-A Benzimidazole and azabenzimidazole IL-17 inhibitor compounds 詹森药业有限公司 2024-06-04 CN disclosed
WO-2023049885-A1 BENZIMIDAZOLE AND AZABENZIMIDAZOLE IL-17 INHIBITOR COMPOUNDS JANSSEN PHARMACEUTICA NV (BE) 2023-03-30 WO disclosed
CN-110191882-B Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them 株式会社大熊制药 2022-09-13 CN disclosed
US-10981917-B2 Heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same DAEWOONG PHARMACEUTICAL CO., LTD. (KR) 2021-04-20 US disclosed
EP-3159335-B1 NOVEL HETEROCYCLIC COMPOUND DAE WOONG PHARMA (KR) 2020-04-29 EP disclosed
US-10590083-B2 Pyridin-2-one derivatives of formula (I) useful as EP3 receptor antagonists JANSSEN PHARMACEUTICA NV (BE) 2020-03-17 US disclosed
US-10399944-B2 Pyridin-2-one derivatives of formula (III) useful as EP3 receptor antagonists JANSSEN PHARMACEUTICA NV (BE) 2019-09-03 US disclosed
US-10336701-B2 Pyridin-2-one derivatives of formula (II) useful as EP3 receptor antagonists JANSSEN PHARMACEUTICA NV (BE) 2019-07-02 US disclosed
US-20190047960-A1 PYRIDIN-2-ONE DERIVATIVES OF FORMULA (II) USEFUL AS EP3 RECEPTOR ANTAGONISTS JANSSEN PHARMACEUTICA NV (BE) 2019-02-14 US disclosed
US-10081634-B2 Heterocyclic compound DAEWOONG PHARMACEUTICAL CO., LTD. (KR) 2018-09-25 US disclosed
WO-2018147626-A1 NOVEL HETEROCYCLIC COMPOUND, ITS PREPARATION METHOD, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME DAEWOONG PHARMACEUTICAL CO., LTD. (KR) 2018-08-16 WO disclosed
EP-3159335-A2 NOVEL HETEROCYCLIC COMPOUND Daewoong Pharmaceutical Co., Ltd. (KR) 2017-04-26 EP disclosed
US-20170088551-A1 NOVEL HETEROCYCLIC COMPOUND Daewoong Pharmaceutical., Ltd. (KR) 2017-03-30 US disclosed
US-8637537-B2 Serine/threonine kinase inhibitors GENENTECH, INC. (US) 2014-01-28 US disclosed
US-20130225620-A1 SERINE/THREONINE KINASE INHIBITORS GENENTECH, INC. (US) 2013-08-29 US disclosed
US-20100222345-A1 NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS FOR OPIOID RECEPTORS SMITHKLINE BEECHAM CORPORATION 2010-09-02 US disclosed
EP-2049481-A2 NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS FOR OPIOID RECEPTORS SmithKline Beecham Corporation (US) 2009-04-22 EP disclosed
WO-2008021851-A2 NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS FOR OPIOID RECEPTORS SMITHKLINE BEECHAM CORPORATION (US) 2008-02-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10336701-B2 Pyridin-2-one derivatives of formula (II) useful as EP3 receptor antagonists PTGER3, PTGER1, PTGER2 MEN1 2556/4885KMT2A 3850/4885ALDH1A1 2314/4885
US-10590083-B2 Pyridin-2-one derivatives of formula (I) useful as EP3 receptor antagonists PTGER3, PTGER1, PTGER2 MEN1 2333/4885KMT2A 4001/4885ALDH1A1 1953/4885
US-20190047960-A1 PYRIDIN-2-ONE DERIVATIVES OF FORMULA (II) USEFUL AS EP3 RECEPTOR ANTAGONISTS PTGER3, PTGER1, PTGER2 MEN1 2556/4885KMT2A 3850/4885ALDH1A1 2314/4885
US-20250122181-A1 BENZIMIDAZOLES AS MODULATORS OF IL-17 IL17A, IL23R, IL2 MEN1 2207/4885KMT2A 2857/4885ALDH1A1 240/4885
US-10981917-B2 Heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same RNASE1, AARS1, DHPS MEN1 1797/4885KMT2A 2757/4885ALDH1A1 2364/4885
US-20130225620-A1 SERINE/THREONINE KINASE INHIBITORS PAK1, AKT1, RB1 MEN1 1300/4885KMT2A 1627/4885ALDH1A1 2874/4885
US-10081634-B2 Heterocyclic compound AARS1, NSUN3, RNASE1 MEN1 2274/4885KMT2A 2809/4885ALDH1A1 1349/4885
US-20100222345-A1 NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS FOR OPIOID RECEPTORS OPRL1, OPRM1, OPRK1 MEN1 4829/4885KMT2A 3326/4885ALDH1A1 3109/4885
US-10399944-B2 Pyridin-2-one derivatives of formula (III) useful as EP3 receptor antagonists PTGER3, PTGER1, PTGER2 MEN1 2604/4885KMT2A 4033/4885ALDH1A1 2320/4885
US-20170088551-A1 NOVEL HETEROCYCLIC COMPOUND AARS1, TARBP1, NSUN3 MEN1 3059/4885KMT2A 3067/4885ALDH1A1 2054/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.